ScreenerHero

FTH Faeth Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · faeththerapeutics.com
24.92USD-7.33%Mkt Cap: 643.94M $P/E: —

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap643.94M USD
Enterprise Value509.00M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-21.09M USD
Revenue/Share—
Last Price24.92 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees29
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.99
PEG—
EV/EBITDA-13.89
EV/Revenue—
P/S—
P/B4.02
EPS (TTM)-60.32
EPS (Forward)-4.49
52W Range
7.45050% of range42.14
52W High42.14 USD
52W Low7.450 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-113.41%
ROA-92.07%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-20.45M USD
CapEx (TTM)16.00K USD
FCF Margin—
FCF Yield0.13%
Net Debt-185.85M USD
Net Debt/EBITDA5.07
Balance Sheet
Debt/Equity0.08
Current Ratio19.69
Quick Ratio19.46
Book Value/Sh6.70 USD
Cash/Share7.21 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJun 17, 2025
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)56.67 USD
Upside (mean)+127.4%
Target Range46.00 USD – 70.00 USD
46.00+127.4% to mean70.00
# Analysts12
Ownership
Shares Out.25.84M
Float18.51M
Insiders4.95%
Institutions79.60%
Short Interest
Short Ratio4.3d
Short % Float5.18%
Short % Out.5.10%
Shares Short1.32M
Short (prev mo.)827.17K
Technical
SMA 5031.83 (-21.7%)
SMA 20024.11 (+3.4%)
Beta-0.29
S&P 52W Chg16.45%
Avg Vol (30d)409.14K
Avg Vol (10d)367.70K
Technical Indicators
RSI (14)33.4
MACD-1.7075
MACD Signal-0.8208
MACD Hist.-0.8868
BB Upper41.14 USD
BB Middle31.86 USD
BB Lower22.57 USD
BB Width58.28%
ATR (14)2.850 USD
Vol Ratio (20d)0.72x